Abstract
A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer
Eleni
Introduction
Breast cancer is the second leading cause of cancer death in women exceeded only by lung cancer [1] . In breast cancer, dissemination of cancer cells with metastatic potential from the primary tumor through the blood or the lymphatics occurs early in the course of disease and is considered the main cause of subsequent disease-related death [2] . There is substantial evidence that the detection of circulating tumor cells (CTCs) in patients with early or metastatic breast cancer is associated with unfavourable prognosis, lack of treatment efficacy and tumor progression [3] [4] [5] [6] [7] [8] [9] . Thus, the detection of CTCs prior to and/ or during therapy has gained considerable interest, since peripheral blood sampling is easy and can be repeated as needed. However, other studies failed to support the prognostic and predictive value of CTCs in breast cancer [10] [11] [12] [13] . These inconsistencies may be related to the sensitivity and specificity of the methods used for CTC isolation and detection. On the other hand, highly sensitive and specific assays have been developed to detect circulating tumor DNA (ctDNA) carrying tumor specific alterations in patients with cancer [14] . The potential of ctDNA analyses to detect occult minimal residual disease and to predict clinical response to therapy and survival in breast cancer is being actively explored [15, 16] .
CTC assays rely on a combination of different enrichment and detection steps in order to enhance their sensitivity and specificity [17] . The technical variability of these assays, the heterogeneity of CTCs, as well as the possible treatment-induced alterations on marker expression, posed significant challenges as to which is the optimal detection method.
The CellSearch TM System, the only method clinically validated and cleared for use in patients with metastatic breast, prostate and colorectal cancer, uses ferrofluid nanoparticles with antibodies against the epithelial cell adhesion molecule (EpCAM), thus separating epithelial cells from the majority of blood cells. Further staining of cells with specific antibodies for cytokeratins (CK), the common leukocyte antigen (CD45), nuclear dye (DAPI) and visualization under microscopy enables the identification of CTCs [3] . The detection of CTCs by the use of CellSearch TM , at any time-point during the course of therapy, was predictive of the progression-free and overall survival of patients with metastatic breast, prostate or colorectal cancer [18] .
Our group has developed a Real-Time quantitative Polymerase Chain Reaction (RTqPCR) assay for the detection of CK19-mRNA in the peripheral blood mononuclear cells (PBMCs) compartment after Ficoll isolation [19] . The presence of CK19 mRNA-positive CTCs has been associated with an unfavourable clinical outcome in patients with either early or metastatic breast cancer. Specifically, the detection of CK19 mRNA-positive cells either before the initiation or after the completion of adjuvant chemotherapy as well as during follow-up, was predictive of poor clinical outcome in patients with early stage breast cancer [7, 8, 20] . In the metastatic setting, the presence of CK19 mRNA-positive cells before the initiation of front-line chemotherapy identifies a group of patients with dismal prognosis [21] .
One limitation of PCR-based assays is that they provide the number of target transcripts according to the actual number of CTCs present in a sample [17] and do not allow the morphologic evaluation of cells. To overcome this limitation, cell-based assays have also been used for the detection and characterization of CTCs. We developed a method of multifluorescent immunostaining of PBMCs spun on glass slides to identify the markers of interest on tumor cells [22] [23] [24] . However, this assay has not as yet been evaluated in comparison to other methods for its performance to detect CTCs.
The aim of the present study was to compare the three assays for the detection of CTCs in patients with early and metastatic breast cancer; the RT-qPCR for CK19 mRNA [19] , the immunofluorescent (IF) assay and the CellSearch TM platform regarding their relative efficiency in detecting CTCs. We also assessed their performance in predicting patients' clinical outcome. 
Materials and Methods
Patients From 2007 to 2010, patients with histologically confirmed early or metastatic breast cancer, treated at the Department of Medical Oncology of the University Hospital of Heraklion and the First Department of Medical Oncology of the IASO General Hospital, Athens, were prospectively tested for the presence of CTCs before the initiation of adjuvant or first-line chemotherapy, respectively. Only patients aged ≥18 years, without a history of a second malignancy within the previous 5 years, except of a skin non-melanoma malignancy or an in situ cervical cancer, were included in the present study. In addition, 26 healthy female blood donors were enrolled as a control group. All patients and healthy donors enrolled in this study gave written informed consent in order to participate and the study was approved by the Ethical and Scientific Committee of our Ιnstitution.
Sample collection
Twenty millilitres (ml) of peripheral blood was collected in EDTA tubes for CK19 mRNA and immunofluorescent analysis [19] . To avoid blood contamination by epithelial cells of the skin, all blood samples were obtained after the first 5ml of blood was discarded.
Blood was diluted with equal volume of 0.9% NaCl and PBMCs were obtained by gradient density centrifugation using Ficoll Hypaque (Sigma Chemical Company, St. Louis, MO) at 670 g for 30 min at 4 ο C. The interface cells were removed, washed twice with 40 mL of sterile PBS at 529 g for 10 min and resuspended in 10mL of PBS. Cell pellets were kept at −80°C until RNA extraction. In parallel, 500.000 PBMCs/slide were cytocentrifuged, air-dried and stored at -80 o C, to be used in immunofluorescence experiments. For the detection of CTCs by the CellSearch TM System, 7.5ml of blood was collected from patients with metastatic disease [3] and 23ml from patients with early disease [6] . Blood was drawn into CellSave Vacutainer tubes (Veridex LLC, JnJ, USA), which contained EDTA and an optimized cell preservative. In the case of healthy female controls, 7.5 ml and 23 ml of blood was collected in order to correspond to the blood volumes evaluated in the metastatic and adjuvant settings, respectively. Images obtained by the CellSearch System were reviewed by readers that had received the appropriate training in image interpretation for the definition of CTCs.
Total RNA isolation and cDNA synthesis Total RNA isolation was performed by using Trizol reagent (Invitrogen, USA) according to the manufacturer's instructions. All preparation and handling steps of RNA took place in a laminar flow hood, under RNAse-free conditions. The isolated RNA was dissolved in RNA storage buffer (Ambion, USA) and stored at -80 o C until used [19] . RNA concentration was determined using Nanodrop Spectrophotometer ND-1000. Reverse transcription of RNA was carried out with the SuperScript TM III Platinum Two-Step RT-qPCR Kit (Invitrogen, USA).
Detection of CTCs by RT-qPCR
The real-time RT-qPCR assay for CK19 mRNA detection was performed as previously described. Briefly, the real-time RT-qPCR assay was performed in a total volume of 10 μL in the LightCycler glass capillaries. For the PCR, 1μL of cDNA was placed into a 9μL reaction volume containing 1μL of the PCR Synthesis. Primers and Probes were provided by TIB MOLBIOL (Berlin, Germany). Τhe analytical details (specificity, sensitivity, cut-off for positivity), the primers and probes used as well as the cycling protocol have been previously described [19] .
RNA integrity was tested by PCR amplification of the PBGD housekeeping gene. Results are expressed as MCF-7 cell equivalents per 5 μg of total-RNA, as determined by the LightCycler System software 3.1. The lower detection limit for positivity of the assay has been determined to be >0.6 MCF-7 cell equivalents/5μg RNA for the patients' PBMCs.
Detection of CTCs by double and triple immunofluorescence (IF)
PBMC cytospins were fixed using cold aceton/methanol (9:1) for 20 min at room temperature and blocked with PBS/5% FBS, 0.9mM CaCl 2 , 0.5mM MgCl 2 for 1 h. Cells were incubated with an anti-CD45 (common leukocyte antigen) rabbit antibody (Santa Cruz, USA) for 1 h along with the corresponding secondary Alexa 555 anti-rabbit antibody (Molecular Probes, Invitrogen, USA) for 45 min followed by the A45-B/B3 mouse antibody (which recognizes the CK8/18 and CK19; Micromet, Germany) for 1 h along with the corresponding secondary fluorescein anti-mouse antibody for 45 min (Molecular Probes, Invitrogen, USA). Negative controls were set for the primary antibodies by omitting the corresponding primary antibody and adding the secondary immunoglobulin G (IgG) isotype antibody. 4',6-diamidino-2-phenylindole (DAPI) antifade reagent (Invitrogen, Carlsbad, CA, USA) was added to each sample for nuclear staining. Cytospins were evaluated by IF microscopy at 40x magnification using the Leica DM 2500 microscope. CK-positive cells were determined as CTCs if they presented no staining for CD45 and met the cytomorphological criteria proposed by Meng et al [25] . (i.e DAPI-positive, high nuclear/cytoplasmic ratio and size larger than white blood cells). For each patient, two slides were analyzed and results are expressed as CK(+) CTCs /10 6
PBMCs. The detection of at least one CK-positive CTC/10 6 PBMCs was required for the definition of CTCpositivity.
To determine the reproducibility of the IF assay for CTC detection, 10 and 100 MCF-7 cells/10 6 PBMCs were spiked into 1x10 6 normal donor PBMCs in triplicate and cytospins of 500.000 PBMCs were prepared. Two random cytospins for each concentration were stained with the CD45/A45-B/B3 antibodies. The detection of at least 1 CK-positive CTC/10 6 PBMCs was required for the definition of CTC-positivity. The experiment was repeated three separate times and results are presented in Table 1 .
In order to investigate the discrepancies observed by CellSearch TM and RT-qPCR in patients, triple IF experiments for the detection of EpCAM, CD45 and CK19, were carried out in PBMC cytospins. PBMC cytospins, prepared as described above, were incubated with the CD45 mouse monoclonal antibody (Dako, Denmark) along with the corresponding secondary anti-mouse antibody labelled with Alexa 633 [Far Red] fluorochrome (Invitrogen, USA) for 45 min, followed by EpCAM rabbit antibody (Abcam, Cambridge, UK) for 1 h, along with the corresponding secondary anti-rabbit antibody labelled with Alexa 555 fluorochrome for 45 min (Invitrogen, USA) and lastly with an anti-CK19 mouse fluorescein isothiocyanate (FITC)-conjugated antibody (Abcam, Cambridge, UK) for 1 h. Finally, CTCs were detected by immunofluorescence using the Ariol System. (Molecular Devices, New Milton, UK). For each patient, two slides were tested and results were expressed as CTCs/10 6 PBMCs.
Isolation and Enumeration of CTCs by the CellSearch

TM
The CellSearch TM System (Veridex, JnJ, USA) was used for the isolation and enumeration of CTCs in peripheral blood. Τhe CellSearch TM Circulating Tumor Cell Kit (Veridex Warren, NJ) was applied for CTC enrichment and enumeration. For the purpose of this analysis, two cut-off values were used to determine CTC positivity in samples; 1 or more and 2 or more CTCs/23ml of blood were used in the adjuvant setting, whereas in the metastatic setting the respective cut-offs were 2 or more and 5 or more CTCs/7.5 ml of blood.
Statistical design and analysis
The aim of this study was to compare the three assays [RT-qPCR for CK19 mRNA, immunofluorescence (IF) and CellSearch TM ] for the detection of CTCs in patients with early and metastatic breast cancer and to assess their performance in predicting patients' clinical outcome. Summary tables (descriptive statistics and/or frequency tables) are provided for all baseline variables and efficacy variables, as appropriate. Continuous variables are summarized with descriptive statistics (n, mean, standard deviation, range, and median). Disease Free Survival (DFS) in the adjuvant setting was defined as the time from study entry until the date of first evidence of clinical or radiological disease recurrence or death from any cause. Progression Free Survival (PFS) in metastatic patients was defined as the time from study entry until clinical or radiological disease relapse or death from any cause. Overall Survival (OS) was measured from the date of study entry until the date of death from any cause or the date of last follow-up.
Qualitative factors were compared by Pearson's Chi-square test or Fisher's exact test whenever appropriate. Differences in positivity rates were assessed using the McNemar test. In addition, the Kappa test was used in all cases to evaluate the agreement between the three molecular methods. The normality of continuous variables was tested using the Kolmogorov-Smirnov test and the Spearman's exact test was used to evaluate the correlation between the three molecular methods. DFS, PFS and OS were estimated using the Kaplan-Meier analysis and the comparisons were computed with the log-rank test.
All statistical tests were two-sided, and p-values <0.05 were considered statistically significant. Data were analyzed using the SPSS statistical software, version 22.0 (SPSS Inc., Chicago, IL, USA).
Results
Patients
Two-hundred consecutive patients with early stage and 164 with metastatic breast cancer were evaluated for CTC detection by the use of RT-qPCR for CK19 mRNA and the CellSearch TM System before the initiation of adjuvant and first-line chemotherapy, respectively. Patient characteristics are depicted in Table 2 (A, B). In 178 of these patients with early and in 105 with metastatic disease, blood samples were also evaluated by the use of IF.
Detection of epithelial cells in the peripheral blood of healthy women
No CK19 mRNA-positive cells were detected in the peripheral blood of 26 healthy female blood donors. Using immunostaining and IF microscopy, 1 out of 26 healthy females tested positive, harboring 1 cell/10 6 PBMCs. In addition, using the CellSearch TM platform, one and two healthy controls had 1 cell/7.5mL and 1 cell/23mL of blood, respectively.
Detection of CTCs in early breast cancer
Using the real time RT-qPCR assay, 36 of 200 (18%) patients with early breast cancer, were CTC-positive at baseline. Using the CellSearch TM system 74 (37%) and 33 (16.5%) of patients had detectable CTCs (cut-offs ≥1 and ≥2, respectively). Among 178 patients evaluated by IF microscopy, 30 (16.9%) had CK-positive CTCs.
At the cut-off of ≥1 CTCs/23 ml of blood for the CellSearch TM system, the CTC-positivity rate with at least one method was 38.5%. However, CTC-positivity according to whether a specific sample from a patient was reported as positive with all three methods was only 2.5%.
Differences in positivity between methods were compared using the Mc Nemar test. Patients were more likely to be CTC-positive using the CellSearch TM (at ≥1) than real-time RT-qPCR (37% vs 18.0%, P<0.001) or IF (37% vs 16.9%, P<0.001). The overall concordance between RT-qPCR and CellSearch TM , defined as the case in which the sample from a patient was reported as positive or negative by both methods, was 62% and 73.5% for the cut-offs of ≥1 and ≥2, respectively (κ=0.088, p=0.161 and κ=0.072, p=0.307, κ-test) . Similarly, the overall agreement between the IF and CellSearch TM was 61.8% and 71.9% for the cut-offs of ≥1 and ≥2, respectively (κ=0.078, p=0.233 and κ=<0, p=0.976, κ-test) . The agreement between the IF and RT-qPCR was 73% (κ=0.086, p=0.248, κ-test). The concordance rates between methods are included in Table 3Α . Table 3B .
Expression of EpCAM and CK19 on CTCs of patients with breast cancer
To investigate the possible contribution of CTC heterogeneity as the cause of discrepancies observed between the 3 methods, triple IF experiments for the detection of EpCAM, CD45 and CK-19 were performed in PBMC cytospins obtained from 72 patients presenting discordance in the detection of CTCs by the CellSearch TM system and RT-qPCR ( Fig. 1 A, B, C 
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EpCAM [CK19(+)/EpCAM(+)], 26% were CK19(-)/EpCAM(+) and 39% CK19(+)/EpCAM(-). The different immunophenotypes of CTCs observed in each patient are depicted in Table 4 . As shown in Table 4 system due to lack of EpCAM expression, were detected, whereas in one case (# 7), CK19(+)/ EpCAM(-) along with CK19(-)/EpCAM(+) CTCs were observed. In the group of discordant cases classified as CTC-positive by CellSearch TM only, 50% of patients had exclusively EpCAM(+)/CK19(-) CTCs (patients # 8, 9, 14, 19, 20, 21, 22, 23) , thus explaining the negative result using the RT-qPCR for CK19 mRNA, 13% (#12, 18) had exclusively CK19(+)/EpCAM(+) CTCs, whereas the remaining patients presented variability in the CTC phenotypes.
Prognostic relevance of CTC detection by the three methods
A total of 172 patients with early breast cancer with available follow up data were evaluated for the prognostic significance of CTC detection. CTCs were identified in 30.8% and 12.8% (cut off ≥ 1 and ≥ 2 CTCs, respectively) of these patients using the CellSearch TM system, in 18.6% by RT-qPCR and in 19.2% by IF. After a median follow up period of 74.8 months (range, 2.1-100.7), 32 (18.6%) patients had experienced disease recurrence and 18 (11.0%) had died. There was no difference in the number of recurrences or deaths among CTC-positive and CTC-negative patients, regardless of the detection method. At the time of analysis, the median disease-free survival and overall survival had not yet been reached.
The prognostic value of CTC detection was also evaluated in 137 metastatic patients. CTCs were detected in 52.6% and 38% of patients with the CellSearch TM system (at ≥ 2 and ≥ 5 CTCs cut-offs, respectively), in 39.4% with RT-qPCR and in 29.5% with IF. After a median follow-up time of 45.6 months (range 0.3 -68.3), the median PFS in CTC-positive versus CTCnegative patients determined using the CellSearch TM at ≥ 2 and ≥ 5 CTCs, was 7.9 compared to 22.4 months (p<0.001) and 7.4 compared to 18.7 months (p<0.001), respectively. On the other hand, no statistically significant difference in the median PFS was detected for patients with or without CTCs according to CK19 mRNA detection (p=0.081) or IF-positivity (p=0.180). The median overall survival in CTC-positive versus CTC-negative patients using the CellSearch TM at ≥ 2 and ≥ 5 CTCs was 23.8 compared to 53.7 months (p<0.001) and 18.5 compared to 47.7 months (p<0.001), respectively. Moreover, CTC-positivity determined by either RT-qPCR or IF, was also associated with significantly reduced median overall survival (29.7 vs 44.9 months, p=0.023 and 26.5 vs 44.9 months, p=0.043, respectively). Representative survival curves are presented in Fig. 2 .
Discussion
Different CTC detection assays exist that vary considerably in the methods and markers used for CTC isolation and visualisation, the volume of blood analyzed as well as the definition of positivity. In addition, given the significant heterogeneity of CTCs, it is not clear whether these methods detect all CTCs or even the same subpopulations of CTCs, since epithelialto-mesenchymal transition, a common feature of CTCs, may preclude CTC identification by the use of epithelial markers [26] [27] [28] . As a consequence, comparison between studies is difficult and therefore, despite the fact that in multiple reports the presence of CTCs has been correlated with patients' outcome, CTCs have not as yet been approved for widespread clinical use. CellSearch TM , an automated system for CTC detection and enumeration, is the only one that has gained regulatory approval for use in patients with metastatic breast, prostate and colorectal cancer. Although the prognostic significance of CTCs in early breast cancer has been shown in several studies [4, [6] [7] [8] 20] , there is currently no generally acceptable method for CTC isolation and detection in this setting.
In the present study we aimed to compare three different methods for the detection of CTCs in patients with early and metastatic breast cancer: i) the automated CellSearch TM system ii) an in-house developed real-time RT-qPCR for the detection of CK19 mRNA in peripheral blood and iii) an immunofluorescent cytokeratin-based method. The main features of these assays are summarized in Table 5 . All three different methods employ the detection of cytokeratins as marker of epithelial cells. However, it should be mentioned here that the immunocytochemical staining of bone marrow aspirates for a broad spectrum Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry of cytokeratins in patients with breast cancer, showed that the true positive rate for the detection of disseminated tumor cells was 52.6±11.5% [29] .
Our results show a significant concordance for CTC detection between RT-qPCR for CK19 mRNA and the CellSearch TM system in the metastatic but not in the adjuvant setting. No agreement was found between the CellSearch TM system and IF, or the RT-qPCR for CK19 mRNA and IF, in either early or metastatic disease. It should be noted however that high numbers of negative events, especially in the early disease setting, were recorded by all three methods. Interestingly, CTC detection by either method was of prognostic relevance in metastatic patients.
In general, previous reports have demonstrated conflicting results regarding the agreement between different methods of CTC detection in metastatic patients. Thus, the comparison between the CellSearch TM system and AdnaTest Breast Cancer, a commercially available molecular method that includes cell isolation by an antibody-mix against EpCAM and MUC-1 linked to magnetic particles followed by real-time PCR for EpCAM, MUC-1 and HER2, revealed a significant agreement in metastatic disease [30] . However, in another study, when the CellSearch TM was compared with AdnaTest Breast Cancer and an in-house developed real-time RT-qPCR assay for CK19 and mammaglobin transcripts in metastatic patients, a substantial variation in CTC detection rates and a moderate concordance between methods was reported [31] . In addition, a comparison of two cell-based detection assays, the CellSearch TM and density centrifugation by Onco-Quick, showed that the CellSearch TM was a more accurate and sensitive method to detect and enumerate CTCs [32] .
In our study, the CTC detection rate among patients with early disease was 37% and 16.5% (at ≥1 and ≥2 CTCs) for the CellSearch TM system, 16.9% using the IF and 18% with real time RT-qPCR. Using a highly sensitive and specific real-time RT-PCR method, 20.6% of 160 patients with early breast cancer had CK-19 mRNA positive cells in peripheral blood [33] . Similarly, in the large prospective SUCCESS trial, 21.5% of patients with early breast cancer had at least one CTC/23 ml of blood by the use of the CellSearch TM system [6] , although in previous studies, up to 30% of early breast cancer patients were identified as CTC-positive with the same platform [34, 35] . In addition, 20.6% of 1221 patients enrolled in the SUCCESS trial had at least one CTC detected with manually performed immunocytochemical staining (MICC) using the anti-CK antibody A45-B/B3 on PBMCs [11] . Interestingly, in our study, although the detection frequencies determined by all three methods were comparable, the positive agreement rates were low and the negative agreement rates were modest, resulting in a significant discordance between methods.
In metastatic breast cancer, 53.7% of patients had ≥ 2 CTCs per 7.5 ml of blood. Using the same cut-off, Cristofanilli et al. reported that the incidence of CTCs was 64% among previously untreated patients with metastatic disease [3] . The CellSearch TM system and the RT-qPCR for CK19 mRNA resulted in comparable detection frequencies in metastatic patients, especially for the cut-off of ≥ 5 CTCs per 7.5 ml. Importantly, in contrast to the early disease setting, a significant concordance between the CellSearch TM system and the RT-qPCR was evident in metastatic disease. This could be related to the increased CTC load as well as to a more genetically homogenous CTC population in metastatic compared to early disease [36] . On the other hand, the comparison between the CellSearch TM system and IF, as well as the RT-qPCR and IF, revealed significant discordance in metastatic patients.
Technical differences in the pre-analytical and analytical procedures employed in each of the detection methods could at least partially explain the observed inconsistency between methods. Indeed, the volume of blood analysed was lower for IF compared to RT-qPCR or the CellSearch TM . Moreover, different CTC isolation techniques were used; automated EpCAMbased immunomagnetic selection was employed for the CellSearch TM system, whereas, a manually operated density gradient centrifugation was used for RT-qPCR and IF. Finally, different cut-off values defined the positivity for each assay.
Another significant factor, potentially contributing to the discordant results due to the assumed CTC heterogeneity, is that the assays used evaluate different CTC markers. To investigate this hypothesis, triple IF experiments using EpCAM, CK19 and CD45 antibodies were performed on PBMC cytospins from patients presenting discordant results by CellSearch TM and RT-qPCR. As shown in Table 4 , the expression of these markers on CTCs presented inter-as well as intra-patient variability. In addition, in almost two thirds of the patients, the variable expression of these markers could explain the observed disagreement between the CellSearch TM and RT-qPCR. The complexity of comparison between different assays regarding CTC prevalence is nicely depicted in the report by Strati et al. evaluating three molecular assays for CTC detection; a singleplex RT-qPCR assay for CK-19, a multiplex RT-qPCR for CK-19, HER-2, MAGE-A3, and PBGD and the AdnaTest Breast Cancer [37] . Importantly, in that study, proanalytical and important analytical variables were kept the same in order to obtain a more precise comparison. When the same target (CK-19) was detected in the same cDNAs with the same set of primers and probes, there was a very good concordance between singleplex RT-qPCR and multiplex RT-qPCR, especially in the metastatic setting. However, discordances between methods were observed when different gene transcripts were used to evaluate CTC positivity, further underscoring the importance of CTC heterogeneity for the detection of CTCs. Interestingly, even when the same target, such as HER2, was detected in the same cDNAs using a different set of primers and different detection systems, the results were not statistically correlated.
Nevertheless, the most important parameter, when comparing different methodologies, is whether they recognize clinically relevant subsets of CTCs. Available evidence suggests that when considering the prognostic significance of CTC detection, the testing method matters. Thus, the CellSearch TM system was found to be superior compared to AdnaTest in predicting clinical outcome in patients with advanced breast cancer [12] . In the SUCCESS trial [6] , the presence of CTCs detected by the CellSearch TM system was associated with poor patient outcome in early disease, whereas in the same trial, the prognostic relevance of CTCs could not be demonstrated by the use of MICC [11] . These results imply that different CTC detection methods may identify different CTC subpopulations which could be differentially associated with patients' clinical outcome. In our study, the prognostic significance of CTC detection could not be demonstrated in early disease. However, the presence of CTCs determined by any one of the three methods was predictive of reduced overall survival in the metastatic setting.
Conclusion
The results of this study suggest that the variability regarding the pro-analytical and analytical procedures of the different assays for CTC detection pose a significant limitation in the implementation of CTCs as a tool for patient stratification in clinical trials and/or their use for clinical decision making. Assays and protocols for CTC isolation, detection and characterization need to be well-defined and standardized in detail and have to be validated in prospective clinical trials for correlations with clinical outcome in specific patient populations.
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